Literature DB >> 29285497

Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window.

Shauna L French1, Justin R Hamilton1.   

Abstract

Entities:  

Year:  2017        PMID: 29285497      PMCID: PMC5733327          DOI: 10.21037/atm.2017.09.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  19 in total

Review 1.  Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

Authors:  R M Scarborough; N S Kleiman; D R Phillips
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

2.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

3.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

4.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

5.  Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.

Authors:  S L French; J F Arthur; H Lee; W S Nesbitt; R K Andrews; E E Gardiner; J R Hamilton
Journal:  J Thromb Haemost       Date:  2016-06-22       Impact factor: 5.824

6.  Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.

Authors:  Leonard C Edelstein; Lukas M Simon; Cory R Lindsay; Xianguo Kong; Raúl Teruel-Montoya; Benjamin E Tourdot; Edward S Chen; Lin Ma; Shaun Coughlin; Marvin Nieman; Michael Holinstat; Chad A Shaw; Paul F Bray
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

7.  Role of thrombin signalling in platelets in haemostasis and thrombosis.

Authors:  G R Sambrano; E J Weiss; Y W Zheng; W Huang; S R Coughlin
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

Review 8.  Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.

Authors:  Shauna L French; Jane F Arthur; Huyen A Tran; Justin R Hamilton
Journal:  Blood Rev       Date:  2014-11-06       Impact factor: 8.250

9.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

10.  Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c.

Authors:  Leonard C Edelstein; Lukas M Simon; Raúl Teruel Montoya; Michael Holinstat; Edward S Chen; Angela Bergeron; Xianguo Kong; Srikanth Nagalla; Narla Mohandas; David E Cohen; Jing-fei Dong; Chad Shaw; Paul F Bray
Journal:  Nat Med       Date:  2013-11-10       Impact factor: 53.440

View more
  3 in total

1.  On the article "Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window".

Authors:  Pancras C Wong; Jing Yang
Journal:  Ann Transl Med       Date:  2018-02

2.  Analysis of the F2LR3 (PAR4) Single Nucleotide Polymorphism (rs773902) in an Indigenous Australian Population.

Authors:  Dian Ningtyas; Russell J Thomson; Volga Tarlac; Shivashankar H Nagaraj; Wendy Hoy; John D Mathews; Simon J Foote; Elizabeth E Gardiner; Justin R Hamilton; Brendan J McMorran
Journal:  Front Genet       Date:  2020-04-30       Impact factor: 4.599

Review 3.  Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?

Authors:  Simeng Li; Volga Tarlac; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.